Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer

NCT01680575 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2017-05-31

No results posted yet for this study

Summary

To develop a robust prediction model to predict the occurrence of grade 3-4 neutropenia induced by adjuvant paclitaxel/carboplatin chemotherapy in patients with epithelial ovarian cancer and to validate this model.

Conditions

  • Epithelial Ovarian Cancer

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Jeong-Yeol Park, M.D., Ph.D. · Asan Medical Center

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01680575 on ClinicalTrials.gov